KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Debt (2021 - 2025)

Halozyme Therapeutics (HALO) has disclosed Non-Current Debt for 5 consecutive years, with $2.1 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 42.29% to $2.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 billion through Dec 2025, up 42.29% year-over-year, with the annual reading at $2.1 billion for FY2025, 42.29% up from the prior year.
  • Non-Current Debt for Q4 2025 was $2.1 billion at Halozyme Therapeutics, up from $800.1 million in the prior quarter.
  • The five-year high for Non-Current Debt was $2.1 billion in Q4 2025, with the low at $787.3 million in Q4 2021.
  • Average Non-Current Debt over 5 years is $1.4 billion, with a median of $1.5 billion recorded in 2023.
  • The sharpest move saw Non-Current Debt soared 89.62% in 2022, then tumbled 46.81% in 2025.
  • Over 5 years, Non-Current Debt stood at $787.3 million in 2021, then skyrocketed by 89.62% to $1.5 billion in 2022, then grew by 0.43% to $1.5 billion in 2023, then rose by 0.44% to $1.5 billion in 2024, then soared by 42.29% to $2.1 billion in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $2.1 billion, $800.1 million, and $1.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.